Page last updated: 2024-12-08

sta-21

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

STA-21: STA-21 inhibits Stat3 DNA binding activity, Stat3 dimerization, and reduces the survival of breast carcinoma cells with constitutive Stat3 signaling; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	363709
CHEMBL ID	1987178
SCHEMBL ID	241178
MeSH ID	M0485588

Synonyms (28)

Synonym
nsc-628869
benz[a]anthracene-1,12-trione, 1,2,3,4,7,12-hexahydro-8-hydroxy-3-methyl-
sta-21
sta21
nsc628869
{benz[a]anthracene-1,7,12-trione,} 1,2,3,4,7, 12-hexahydro-8-hydroxy-3-methyl-
8-hydroxy-3-methyl-3,4-dihydrobenzo[a]anthracene-1,7,12(2h)-trione
NCI60_009338
8-hydroxy-3-methyl-3,4-dihydro-2h-benzo[a]anthracene-1,7,12-trione
8-hydroxy-3-methyl-3,4-dihydrotetraphene-1,7,12(2h)-trione
FT-0673176
S7951
SCHEMBL241178
CHEMBL1987178
AC-33639
111540-00-2
sta 21
nsc 628869
(+-)-ochromycinone
sta-21, >=95% (hplc)
AKOS032945165
BCP20158
CCG-267534
BS-51925
HY-18061
CS-0007205
(rac)-sta-21;ta 21
E85712

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (25.00)	29.6817
2010's	8 (66.67)	24.3611
2020's	1 (8.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	68.00 (24.57)
Research Supply Index	2.71 (2.92)
Research Growth Index	4.89 (4.65)
Search Engine Demand Index	109.75 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (68.00)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (7.69%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (92.31%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.48	2	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.48	2	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.08	1	0
ag-490 [no description available]	2.46	2	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	4.37	1	1
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.08	1	0	organic cation

Condition	Relationship Strength	Studies	Trials
Allergic Encephalomyelitis [description not available]	2.6	1	0
Innate Inflammatory Response [description not available]	2.59	2	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.59	2	0
Adenocarcinoma, Basal Cell [description not available]	2.15	1	0
Cancer of Stomach [description not available]	2.15	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	7.15	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.15	1	0
Diffuse Large B-Cell Lymphoma [description not available]	2.08	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	2.08	1	0
Adjuvant Arthritis [description not available]	2.52	2	0
Rheumatoid Arthritis [description not available]	7.52	2	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.52	2	0
Disease Exacerbation [description not available]	2.15	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.15	1	0
Bladder Cancer [description not available]	2.04	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.04	1	0
Palmoplantaris Pustulosis [description not available]	4.37	1	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	9.37	1	1
Breast Cancer [description not available]	2.02	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.02	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.02	1	0

chemdatabank.com